Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Indinavir 800 mg q8h vs 1200 mg q12h in HIV
NCT00002208Phase 3Completed
- Sponsor
- Merck & Co.
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of indinavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Merck & Co. Primary endpoints: Antiviral activity (Viral RNA suppression) at 24 weeks and Safety and Tolerability at 24 weeks. Status: completed.
02
Drugs
indinavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00002208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002208.